LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SPRY
ARS Pharmaceuticals, Inc.
There isn't enough reported data to score SPRY yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SPRY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
SPRY's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SPRY PE Valuation
SPRY has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SPRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SPRY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SPRY on earnings quality, reporting a profit while its opponent remains loss making.
SPRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.01 | -$1.20 |
| Q2 2026 | -$2.17 | -$1.68 |
| Q1 2026 | -$2.00 | -$1.84 |
| Q4 2025 | -$1.74 | -2275% |
| Q3 2025 | -$0.81 | -$0.30 |
| Q2 2025 | -$0.49 | -$0.02 |
| Q1 2025 | -$0.16 | +$0.36 |
| Q4 2024 | $0.08 | +$0.65 |
SPRY is still losing money, but less than at its worst: $2.01 per share over the past year, against $2.72 at its worst in early 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SPRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SPRY on profitability, with a higher operating margin.
SPRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.7M | +16% |
| Q2 2026 | $33.7M | +114% |
| Q1 2026 | $22.7M | +184% |
| Q4 2025 | $28.1M | -68% |
| Q3 2025 | $32.5M | +1472% |
| Q2 2025 | $15.7M | +3043% |
| Q2 2024 | $500K | +4900% |
SPRY's revenue is recovering but still below its 2024 peak: $38M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +73 points |
| Q2 2026 | -183% | +120 points |
| Q1 2026 | -265% | +201 points |
| Q4 2025 | -148% | -202 points |
| Q3 2025 | -164% | +888 points |
| Q2 2025 | -303% | +2765 points |
| Q1 2025 | -466% | N/A |
| Q4 2024 | 55% | N/A |
SPRY's operating margin was −91% last quarter, up 73 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SPRY on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | +$13.5M |
| Q2 2026 | -$60.9M | -$21.3M |
| Q1 2026 | -$44.9M | -$4.1M |
| Q4 2025 | -$43.5M | -204% |
| Q3 2025 | -$47.2M | -$32.6M |
| Q2 2025 | -$39.6M | -$32.3M |
| Q1 2025 | -$40.8M | -$34M |
| Q4 2024 | $41.7M | +$59M |
SPRY has burned cash in almost every quarter: −$183M over the past year, against −$86M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SPRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SPRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +373K shares |
| 1 year | +0.9% | +878K shares |
| 3 years | +4.3% | +4.1M shares |
| 5 years | +186% | +64.8M shares |
| Available history | +201% | +66.6M shares |
SPRY has 100M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SPRY Net Leverage
SPRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SPRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 14.3 | Oversold |
SPRY's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SPRY PE vs Healthcare Sector
| Metric | SPRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SPRY has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SPRY on trend strength, trading above more of its moving averages.
SPRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.80 | 0.3% above |
| 20 week MA | $5.13 | 26% below |
| 50 week MA | $7.64 | 50% below |
| 100 week MA | $10.2 | 63% below |
| 200 week MA | $9.31 | 59% below |
SPRY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SPRY on returns for 2026, with the stronger performance.
SPRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.0 | $35.8 | +43% |
| 2021 | $35.8 | $6.65 | -81% |
| 2022 | $6.65 | $8.08 | +22% |
| 2023 | $8.08 | $5.48 | -32% |
| 2024 | $5.48 | $10.8 | +97% |
| 2025 | $10.8 | $11.4 | +5.5% |
| 2026 YTD | $11.4 | $3.81 | -67% |
SPRY is down 67% so far in 2026, after finishing higher in four of the previous six years.